Department of Pharmaceutical Microbiology Faculty of Pharmacy, Istanbul University, Beyazit, Istanbul, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
J Glob Antimicrob Resist. 2019 Jun;17:137-141. doi: 10.1016/j.jgar.2018.12.004. Epub 2018 Dec 18.
Infections caused by multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) are a growing problem because of the limited options for treatment. The number of antimicrobials that are currently being developed is still insufficient to control this global threat. Combination therapies of antibiotics with different antimicrobial mechanisms have been proposed as the best options for treating MDR A. baumannii infections. The objective of this study was to investigate the in-vitro effectiveness of ceftazidime/avibactam alone or in combination with antibiotics against MDR A. baumannii isolates using time-kill assays.
Forty clinical MDR strains were screened, and minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of ceftazidime/avibactam, colistin, levofloxacin, meropenem, tigecycline, and tobramycin were determined by microbroth dilution method. The in-vitro synergistic activities of ceftazidime/avibactam with antibiotic combinations were determined by time-kill assays at 1× MIC and 4× MIC against five MDR A. baumannii isolates.
Based on MIC results, all isolates of A. baumannii were resistant to ceftazidime/avibactam, except for AB-5. All isolates were found to be resistant to meropenem and levofloxacin. At 4× MIC, all of the tested antibiotics showed bactericidal effect (≥3logkilling). The synergistic activities of ceftazidime/avibactam+colistin, ceftazidime/avibactam+tobramycin and ceftazidime/avibactam+tigecycline combinations at 1× MIC were observed against studied 5/5, 4/5 and 4/5 strains, respectively. Furthermore, all of the tested combinations at 4× MIC were additive at 24h. No antagonism was observed.
The findings of this study suggest that a significant bactericidal effect was seen with all tested combinations. These findings present significant implications for antibiotic choice for the treatment of infections caused by MDR A. baumannii.
由于治疗选择有限,多重耐药(MDR)鲍曼不动杆菌(A.baumannii)引起的感染问题日益严重。目前正在开发的抗菌药物数量仍然不足以控制这一全球威胁。具有不同抗菌机制的抗生素联合治疗已被提议作为治疗 MDR A.baumannii 感染的最佳选择。本研究的目的是通过时间杀伤试验研究头孢他啶/阿维巴坦单独或联合抗生素治疗 MDR A.baumannii 分离株的体外有效性。
筛选了 40 株临床 MDR 株,采用微量肉汤稀释法测定头孢他啶/阿维巴坦、多粘菌素、左氧氟沙星、美罗培南、替加环素和妥布霉素的最小抑菌浓度(MIC)和最小杀菌浓度(MBC)。通过时间杀伤试验,在 1×MIC 和 4×MIC 下,测定头孢他啶/阿维巴坦与抗生素联合对 5 株 MDR A.baumannii 分离株的体外协同活性。
根据 MIC 结果,除 AB-5 外,所有 A.baumannii 分离株均对头孢他啶/阿维巴坦耐药。所有分离株均对美罗培南和左氧氟沙星耐药。在 4×MIC 时,所有测试抗生素均表现出杀菌作用(≥3log 杀灭)。头孢他啶/阿维巴坦+多粘菌素、头孢他啶/阿维巴坦+妥布霉素和头孢他啶/阿维巴坦+替加环素组合在 1×MIC 时对研究的 5/5、4/5 和 4/5 株均显示协同作用。此外,在 24 小时时,所有测试组合在 4×MIC 时均为相加作用。未观察到拮抗作用。
本研究结果表明,所有测试组合均显示出显著的杀菌作用。这些发现对抗生素选择治疗 MDR A.baumannii 引起的感染具有重要意义。